# Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

> **NCT00950742** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00950742
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-01
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950742, "Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00950742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*